ASLN vs. CANF, SONN, ALLR, UPXI, MAAQ, SYRS, ATNF, ARTL, GRI, and PLRZ
Should you be buying ASLAN Pharmaceuticals stock or one of its competitors? The main competitors of ASLAN Pharmaceuticals include Can-Fite BioPharma (CANF), Sonnet BioTherapeutics (SONN), Allarity Therapeutics (ALLR), Upexi (UPXI), Mana Capital Acquisition (MAAQ), Syros Pharmaceuticals (SYRS), 180 Life Sciences (ATNF), Artelo Biosciences (ARTL), GRI Bio (GRI), and Polyrizon (PLRZ). These companies are all part of the "pharmaceutical products" industry.
ASLAN Pharmaceuticals vs.
ASLAN Pharmaceuticals (NASDAQ:ASLN) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends, community ranking and institutional ownership.
Can-Fite BioPharma has lower revenue, but higher earnings than ASLAN Pharmaceuticals. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Can-Fite BioPharma had 6 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 6 mentions for Can-Fite BioPharma and 0 mentions for ASLAN Pharmaceuticals. Can-Fite BioPharma's average media sentiment score of 0.17 beat ASLAN Pharmaceuticals' score of 0.00 indicating that Can-Fite BioPharma is being referred to more favorably in the news media.
ASLAN Pharmaceuticals has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.
Can-Fite BioPharma's return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity.
58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
ASLAN Pharmaceuticals currently has a consensus price target of $76.00, indicating a potential upside of 12,566.67%. Can-Fite BioPharma has a consensus price target of $14.00, indicating a potential upside of 673.48%. Given ASLAN Pharmaceuticals' higher possible upside, research analysts clearly believe ASLAN Pharmaceuticals is more favorable than Can-Fite BioPharma.
ASLAN Pharmaceuticals received 193 more outperform votes than Can-Fite BioPharma when rated by MarketBeat users. Likewise, 63.49% of users gave ASLAN Pharmaceuticals an outperform vote while only 9.86% of users gave Can-Fite BioPharma an outperform vote.
Summary
Can-Fite BioPharma beats ASLAN Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get ASLAN Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ASLAN Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ASLN) was last updated on 2/22/2025 by MarketBeat.com Staff
Free ASLN Stock Alerts